A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults

NCT02239172 Phase 1 COMPLETED

The purposes of this study is to evaluate and compare the safety, reactogenicity, and tolerability of the PA83-FhCMB vaccine candidate delivered at 4 dose levels with Alhydrogel

Details

Lead sponsor	Fraunhofer, Center for Molecular Biotechnology
Phase	Phase 1
Status	COMPLETED
Enrolment	30
Start date	2014-08
Completion	2015-05

Conditions

• Anthrax

Interventions

• PA83-FhCMB

Primary outcomes

• Number of Participants with Adverse Events — Up to 3 months

Countries

United States